Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jack Casas

Interventional Cardiology Muskogee, OK Medical Doctor

NPI 1194836684 CMS profile 235372

350 S 40Th St, Muskogee, OK 74401

Open in the dashboard

General payments

$21,438

229 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jack Casas of Muskogee, OK is reported in the CMS Open Payments database as having received $21,438 across 229 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,975 26
2024 General $439 19
2023 General $6,606 46
2022 General $1,658 31
2021 General $3,986 17
2020 General $4,785 32
2019 General $1,989 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jack Casas
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Jack Casas were reported at $1,975. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Jack Casas Interventional Cardiology median Middle half National median
2019 $1,989 $1,097 $329–$3,048 $163
2020 $4,785 $473 $161–$1,480 $114
2021 $3,986 $677 $233–$1,827 $132
2022 $1,658 $978 $333–$2,724 $149
2023 $6,606 $1,136 $382–$2,986 $160
2024 $439 $1,181 $395–$3,326 $164
2025 $1,975 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $13,566 83 payments
  2. Philips Electronics North America Corporation $5,414 71 payments
  3. Medtronic Vascular, Inc. $1,474 23 payments
  4. Abiomed $264 9 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $158 15 payments
  6. Abbott Laboratories $158 8 payments
  7. Boston Scientific Corporation $144 9 payments
  8. Silk Road Medical, Inc. $65 1 payment
  9. Novartis Pharmaceuticals Corporation $59 3 payments
  10. Kestra Medical Technology Services, Inc. $21 1 payment
  11. Other $114 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $9,601 43 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,200 1 payment
  3. Food and Beverage $4,180 184 payments
  4. Consulting Fee $3,457 1 payment
Products named General payments · program years 2019–2025
  1. Spectranetics Undiv $4,299 2 payments
  2. Resolute $3,786 1 payment
  3. MICRA Pacemakers $1,326 10 payments
  4. EVERA MRI XT DR SURESCAN $1,297 10 payments
  5. RESOLUTE ONYX $668 14 payments
  6. AURORA EV-ICD MRI SURESCAN $391 7 payments
  7. AZURE XT DR MRI SURESCAN $282 5 payments
  8. Micra Pacemakers $217 9 payments
  9. Stellarex Short $178 4 payments
  10. Impella $170 6 payments
  11. Other $2,260 134 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 87 billing codes

Paid by Medicare

$130,605

Medicare's payments for the services billed

Medicare patients

1,488

Average age 73

Services billed

3,170

833 women, 655 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 43%
Ischemic heart disease 40%
Heart failure 36%
Chronic kidney disease 36%
Atrial fibrillation 31%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

229 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record